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A B S T R A C T
Recently there has been an increased interest to develop specialised dosage forms that are better suited to
specific patient populations, such as paediatrics and geriatrics. In these patient populations the acceptability of
the oral dosage form can be paramount to the products success. However, many Active Pharmaceutical
Ingredients (APIs) are known to cause an aversive taste response. One way to increase the acceptability and to
enhance the palatability of the formulation is to design coated taste-masked particulate-based dosage forms. The
masking of poorly tasting drugs with physical barriers such as polymer coatings can be utilised to prevent the
release of drug within the oral cavity, thus preventing a taste response. However, currently, there are few
assessment tools and models available to test the efficiency of these particulate-based taste-masked formulations.
The rat brief access taste aversion model has been shown to be useful in assessment of taste for liquid dosage
forms. However, the applicability of the rat model for particulate-based taste masked formulations is yet to be
assessed. It is not understood whether dissolution, solubility and thus exposure of the drug to taste receptors
would be the same in rat and human. Therefore, rat saliva must be compared to human saliva to determine the
likelihood that drug release would be similar within the oral cavity for both species. In this study rat saliva was
characterised for parameters known to be important for drug dissolution, such as pH, buffer capacity, surface
tension, and viscosity. Subsequently dissolution of model bitter tasting compounds, sildenafil citrate and efa-
virenz, in rat saliva was compared to dissolution in human saliva. For all parameters characterised and for the
dissolution of both drugs in rat saliva, a substantial difference was observed when compared to human saliva.
This discrepancy in saliva parameters and dissolution of model drugs suggests that preclinical taste evaluation of
particulate-based taste-masked formulations suggests rat is not a good model for predicting taste of solid dosage
forms or undissolved drug where dissolution is required. Alternative preclinical in vivo models in other species,
or improved biorelevant in vitro models should be considered instead.
1. Introduction
The oral route is the most popular and convenient route for drug
administration [1]. For the prescription of medicinal products to pa-
tient populations such as paediatrics and geriatrics the acceptability of
a solid oral dosage form can be paramount to the products success [2].
There are several challenges to overcome when designing solid oral
dosage forms for children and older adults. For example, children can
have issues with conventional solid dosage forms due to poor palat-
ability, limited dose flexibility, difficulty swallowing, recalcitrance, and
differences in anatomy and physiology [2–4]. Therefore, there can be
an impact on therapeutic performance of the product. For paediatrics,
there have also been recent developments in European Union (EU)
legislation (Reg 1901/2006/EU and Reg 1902/2006/EU) stating that
new medicines coming to commercial markets must demonstrate pae-
diatric suitability [5]. Geriatrics are also receiving similar attention
with calls for an update in legislation for geriatric drug development
[6,7]. Consequently, there have been increased discussions on the de-
velopment of patient-centric particulate-based oral dosage forms for
these specific populations. Many Active Pharmaceutical Ingredients
(APIs) and excipients are known to cause an aversive taste response [8].
An unpleasant taste has been shown to greatly affect acceptability of a
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dosage form [9]. Taste-masking strategies are commonly used to
overcome these challenges. Particulate-based oral dosage forms can
have a polymer coating applied to provide a physical barrier between
the aversive tasting API and taste receptors within the oral cavity. The
addition of coatings to particulates to prevent a taste response reports
have shown a significant increase in palatability of dosage forms when
compared to API alone [10]. This demonstrates the effectiveness of
coatings in particulate-based formulations for taste-masking and in-
creasing acceptability in paediatrics. Particulate-based oral dosage
forms may be used for better acceptability in paediatrics due to en-
hanced palatability [11], flexible dosing, and improved swallowability
[12]. Particulate-based oral formulations such as minitablets, sprinkle
capsules, suspensions, and granules are intended to be swallowed from
the oral cavity intact. An appropriate preclinical assessment method is
hence required to investigate the efficiency of taste-masking in parti-
culate-based formulations.
Currently the most common method for taste evaluation for solid
oral dosage forms is using human taste panels [13]. However, target
populations that require taste-masked formulations, such as paediatrics,
may not be suitable for this assessment method due to ethical concerns
[13]. In addition, these human trials are expensive, resource intensive,
and may cause significant delays to drug development timelines.
Therefore, there are limited opportunities to conduct paediatric taste
panel studies as part of a clinical trial. In vitro drug release and dis-
solution studies can be used for the determination of drug released from
particulate-based taste-masked formulations, to determine if the con-
centration is above the taste threshold and has unacceptable taste.
However, there is no general consensus and limited studies on what
parameters and models should be used in an oral cavity dissolution test
[14]. What is agreed on is that biorelevant dissolution testing is of great
value and allows for a robust assessment method with better predictions
of in vivo behaviour for the formulations of interest [15–19].
Currently the most common preclinical in vivo taste evaluation
method for liquid dosage forms is the Brief-Access Taste Aversion
(BATA) method. Often mice and rats are deprived of water for 16–24 h
for motivation to drink. Then the animal is placed into a ‘lickometer’
apparatus which records the number of licks that the rodent makes for
different concentrations of the drug presented in several sipper tubes. A
high number of licks (relative to a suitable control) indicates an ac-
ceptable taste whilst those solutions with aversive taste will suppress
the number of licks [20]. It has been reported that the taste aversion
data of model bitter tasting drugs in this rodent model has good cor-
relation to human taste data [21–23]. What needs to be explored is
whether the BATA method in rats could be adapted to also allow the
assessment of particulate-based taste-masked formulations. As the taste
response associated with particulate-based taste-masked formulations is
dependent on the degree of drug release within the oral cavity, it is
imperative to understand the characteristics of the rat oral cavity to
investigate the applicability of the rat taste aversion model to particu-
late-based formulations.
The dissolution of solid dosage forms in the rat oral cavity is de-
pendent on the physicochemical characteristics of rat saliva, the dis-
solution media of the rat oral cavity. Therefore, further investigation is
needed to determine rat saliva physiochemical characteristics and to
assess drug dissolution of model bitter tasting APIs in saliva. In this
study two model bitter APIs (sildenafil citrate, and efavirenz) were used
to compare their dissolution in human and rat saliva.
Sildenafil citrate acts as a selective inhibitor of cGMP-specific
phosphodiesterase type 5 (PDE 5) and is used primarily in the treatment
of erectile dysfunction. However, sildenafil citrate also has therapeutic
applications in the management of paediatric pulmonary hypertension.
Sildenafil citrate is a BCS Class II drug that is known to produce a bitter
taste response [20]. Efavirenz is in the non-nucleoside reverse-tran-
scriptase inhibitor (NNRTI) family of anti-retroviral therapy that is used
in the treatment of human immunodeficiency virus (HIV), including the
treatment of paediatric HIV. It is a BCS Class II drug that is bitter tasting
and gives burning mouth syndrome [24]. Both these model drugs have
clinical use for paediatric populations, and both required formulation
strategies to overcome issues with taste. A brief summary of physico-
chemical properties of sildenafil citrate and efavirenz is shown in
Table 1.
Therefore, the aim of the present work was to determine if rat saliva
has similar physicochemical properties to human saliva, and drug dis-
solution properties for potential adaptation of a rat taste preclinical
taste model to the assessment of particulate-based taste-masked for-
mulation
2. Materials and methods
Sildenafil citrate API powder was donated by Pfizer Ltd. (Sandwich,
UK). Efavirenz API powder was purchased from ChemShuttle (Wuxi
City, China). Pilocarpine hydrochloride was purchased from Sigma-
Aldrich (UK). Methyl-tert-butyl ether (MTBE) was purchased from
Fisher Scientific (UK). All solvents used in the study were HPLC grade
or higher.
2.1. Collection of human saliva from healthy adult volunteers
Human saliva was collected in accordance with Ethics Reference
Number: R12122013 from Faculty of Medicine and Health Sciences,
Nottingham University Hospitals, as previously described [28,29]. In-
formed written consent was obtained from all volunteers. All data was
held in agreement with the Data Protection Act. Exclusion criteria for
the volunteers included chronic or acute illness in the past 3months,
cold or flu symptoms, oral health concerns, and taking medication
(except contraceptives). Before collection of saliva (at least 2 h prior)
volunteers were asked to not eat, smoke, drink or use oral hygiene. To
avoid differences in saliva composition due to circadian rhythms, all
saliva was collected between 14:00 and 16:00 h.
Participants were asked to chew on 5 cm×5 cm square of Parafilm®
for stimulated saliva (SS), which is a known inert material that is widely
used for mechanical stimulation of saliva [30–33]. To donate saliva,
participants were asked to lean forward and drain saliva into sterile
polypropylene graduated centrifuge tubes (Grenier Bio-One, UK) via
sterile disposable funnels. Saliva samples were then flash frozen in li-
quid nitrogen and stored at −80 °C. In total, four volunteers donated
saliva. The donated saliva was pooled, characterised, and used in dis-
solution studies.
Table 1
Physicochemical parameters of sildenafil citrate and efavirenz. Molecular
weight, Log P, and pKa values were taken from ACD/Labs software (v5.0.0.184)
[27].
Drug Molecular weight
(g/mol)
Log P pKa pH solubility
(mg/mL), 37 °C
Sildenafil
citrate
666.7 2.3 Sildenafil free
base:
6.5, 9.2
Adapted from
[25]
pH 3.0: 6.97
pH 4.0: 7.08
pH 5.0: 2.07
pH 6.0: 0.11
pH 7.0 – pH 10.0:
< 0.04
pH 11.0: 0.32
Efavirenz 315.7 4.8 10.2 Adapted from
[26]
pH 1.2: 0.020
pH 4.5: 0.019
pH 6.8: 0.011
pH 7.4: 0.082
pH 9.0: 0.16
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2.2. Collection of stimulated rat saliva
All procedures for rat saliva collection were reviewed and approved
by the Rutgers University Institutional Animal Care and Use Committee.
Male Sprague-Dawley rats (Envigo, USA) 8 – 12weeks old were used for
saliva collection. Animals were housed under controlled temperature,
twelve-hour light/dark cycle and free access to food and water.
For the collection of rat saliva there are two main approaches de-
scribed in literature. Firstly, intra-oral cannulation of salivary duct or-
ifices to gather saliva from their respective glands [34–38]. Secondly,
an elevation collection method, that collects saliva passively from the
mouth from anaesthetised animals [39,40].
The saliva collection method used in this work was an optimisation
of the previously reported non-invasive, elevation sialometric method
[39,40]. This sialometric method involves anaesthetising animals, then
administering a sialogogue agent, and orientating animals head in a
downwards slope to which then saliva can passively flow into collection
tubes. General anaesthesia was induced with inhalation of 3% iso-
flurane, and anaesthesia was maintained throughout collection with
isoflurane via a nose cone. Specific 3D printed platforms were necessary
for efficient saliva collection as the platform must hold a number of
components at once: a nose cone for anaesthesia, the collection tube,
orientation of the animals’ head downwards without impacting cardi-
ovascular parameters, and engagement of the lower incisors to keep the
mouth open during collection, as shown in Fig. 1 [41]. These platforms
were tapered in height from 50mm to 10mm, width 100mm, depth
125mm.
Immediately before saliva collection 2mL saline was injected for
fluid replacement by subcutaneous bolus. Saliva was then stimulated by
intraperitoneal administration of 2mg/kg pilocarpine hydrochloride.
Immediately following the injection, the animals were positioned on
top of the platforms for saliva collection. After collection, the animals
were left to recover for 48 h, and were given an additional 2mL saline
replacement 24 h post collection. Immediately following collection, pH
of individual saliva samples was measured with a Mettler Toledo S220
Seven Compact pH/ion meter, connected to an InLab Micro pH elec-
trode (Mettler Toledo, Switzerland). Saliva samples were then flash
frozen in liquid nitrogen and stored at −80 °C until further analysis.
2.3. Characterisation of rat and human saliva
Pooled stimulated human saliva was characterised for: pH, buffer
capacity, viscosity, and surface tension as previously described [28,29].
Individual rat saliva samples were tested for pH immediately after
collection. Pooled stimulated rat saliva was characterised for: buffer
capacity, viscosity, and surface tension. Two hundred µL of rat saliva,
and 4mL of human saliva samples were brought to 37 °C in a water
bath. Initial pH was determined using Mettler Toledo S220 Seven
Compact pH/ion meter, connected to an InLab Micro pH electrode.
Saliva samples were titrated with 0.01M HCl until pH had decreased by
1 unit. Buffer capacity was then calculated in mmol H+/L, by the
amount of acid added. A Modular Compact Rheometer MCR 302 (Anton
Paar GmbH, Germany) was used with a cone-plate set up to measure
viscosity of saliva. The cone used was a CP50-2-SN30270, diameter
49.972mm, angle 2.016°, truncation 211 µm. Viscosity measurements
were taken at 37 °C over three logarithmic decades for shear rate from 1
to 1000 s−1 with measurements taken at 8 points per decade. Data was
recorded on Rheoplus software (Anton Paar GmbH, Germany) for
analysis. A DSA 100 Drop Shape Analyser with DSA 4 software (Kruss
GmbH, Germany) was used to measure surface tension of saliva by
using the pendant drop method with Laplace-Young computational
method. Temperature was set to 37 °C using an MB-5 heat circulator
and water bath (Julabo GmbH, Germany).
2.4. Oral cavity dissolution studies of sildenafil citrate and efavirenz in
pooled rat and human stimulated saliva
The volume of saliva used in the oral cavity dissolution method was
based on average saliva volumes reported for adult humans [42,43].
Multiple small-scale dissolution vessels were kept at 37 °C each with a
magnetic stirrer in a setup as was previously described for human saliva
dissolution studies [29]. Separate dissolution vessels were used in
parallel to measure the concentration of drug over different time points.
At each time point pH of saliva was recorded. Pooled stimulated saliva
(200 µL) was added to 10mg of sildenafil citrate. Pooled stimulated
saliva (250 µL) was added to 50mg of efavirenz. Volume of saliva and
amount of drug were selected to give relevant clinical dose in humans.
A constant stirring speed of 200 rpm was used to allow adequate mixing
of solid material in relatively small volumes of media. Both rat and
human stimulated saliva were used as dissolution media for the two
drugs of interest. After each time point was reached, the entire contents
of the dissolution vials were transferred to Costar Spin-X centrifuge
tubes with 0.22 μm pore CA filters (Corning B.V. Life Sciences, UK), and
centrifuged for 10min at 17,000× g.
2.5. Analytical procedures
Filtered dissolution sample (10 μL) was transferred to a glass test
tube, to which the following was added: 10 μL of internal standard (IS),
90 μL of blank saliva (for further dilution of the drug to the range sui-
table for HPLC analysis), and 400 μL of 50:50 acetonitrile (ACN), me-
thanol mixture (stored at −20 °C). After filter centrifugation of efa-
virenz samples, 180 μL of filtered dissolution sample was transferred to
a glass test tube, to which 20 μL of internal standard (IS), and 400 μL of
Fig. 1. Schematic description of the non-invasive sialometric method to collect stimulated saliva from anaesthetised rats.
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acetonitrile/methanol mixture (50:50, stored at −20 °C) was added.
Then, the test tubes were vortex mixed for 2min. Next, methyl-tert-
butyl ether (MTBE) was added to each test tube (3mL for sildenafil,
4 mL for efavirenz), and vortex mixed at 1200min−1 for 10min in a
multi-tube vortexer (VWR VX-2500). Then, samples were centrifuged at
1690× g for 10min. Following centrifugation, the organic layer was
transferred and evaporated to dryness under nitrogen. The dry residue
was then reconstituted with 100 μL of mobile phase (44% ACN, 56%
water). Reconstituted samples were then vortex mixed and centrifuged,
before transferring the contents to HPLC vials. All calibration and
quality control samples underwent the same sample preparation pro-
cedures as stated for the dissolution samples.
Waters (Milford, USA) 2695 separations module HPLC system
equipped with Waters 996 PDA UV detector was used. Samples in the
autosampler were maintained at 4 °C and the column oven was set to
40 °C. Empower 2 software was used for data processing. Separation of
the extracted sildenafil citrate and efavirenz samples were achieved
with Waters Xterra C18 2.1× 100mm, 3.5 μm particle size column,
with Xterra MS C18 2.1×10mm 3.5 μm guard column and pre-column
filter including a 0.5 μm stainless steel frit. Mobile phase was 56% 0.2M
ammonium acetate buffer (pH 7.0) and 44% ACN, eluted at isocratic
conditions at 0.3mL/min for sildenafil citrate, and 0.2mL/min for
efavirenz. Bifonazole was used as the internal standard (IS) for silde-
nafil. Sildenafil citrate was used as the internal standard (IS) for efa-
virenz. Sildenafil citrate and bifonazole were detected at 224 nm at 3.1
and 7.9min respectively. Efavirenz and sildenafil were detected at
290 nm and 224 nm at 11.2 and 4.0min respectively. Validation of both
assays for these compounds was performed following FDA guidelines
[44]. A summary of validation parameters is shown in Tables 2 and 3
for sildenafil and efavirenz respectively. Calibration curves were con-
structed in the concentration ranges expected from dissolution of the
drug in saliva. Calibration curves all had correlation coefficient (r2)
values of> 0.99.
2.6. Statistical analysis
Results are expressed as mean ± standard deviation (SD). pH,
buffer capacity and surface tension were analysed with unpaired t-test.
Dissolution and viscosity results were analysed with one-way ANOVA
and Sidak’s multiple comparisons test. A p < 0.05 was considered to
represent a significant difference.
3. Results
3.1. Characterisation of rat and human saliva
Stimulated rat (RS SS) and human saliva (HS SS) were characterised
for: pH, buffer capacity, viscosity, and surface tension (Fig. 2). The
characterisation results for human saliva were in agreement with our
previously reported works [28,29]. All characterisation parameters of
stimulated rat saliva were observed to be different from stimulated
human saliva. Stimulated rat saliva had dramatically higher pH com-
pared to stimulated human saliva (Fig. 2A), but substantially lower
buffer capacity (Fig. 2B) and surface tension (Fig. 2C). Stimulated rat
saliva had also statistically significantly lower (p < 0.05) viscosity at
shear rates from 1.33 to 10.0 s−1 compared to stimulated human saliva,
whilst no significant differences between rat and human saliva were
found at 1 s−1 nor in the range of 13.33–1000 s−1 shear rates (Fig. 2D).
3.2. Dissolution of sildenafil citrate in saliva
Dissolution of sildenafil citrate API powder (50mg dose equivalent)
was assessed in pooled stimulated rat and human saliva (equivalent to
1.0 mL residual volume of saliva in humans). Concentrations of silde-
nafil in human saliva were profoundly higher than the concentrations of
sildenafil in rat saliva, as shown in Fig. 3. Changes in pH of saliva over Ta
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sildenafil dissolution time course are shown in Fig. 4. In both HS and RS
saliva pH was shown to reduce to pH 4.5 within the first time point
(1min).
3.3. Dissolution of efavirenz in saliva
Dissolution of efavirenz API powder (200mg dose equivalent) was
assessed in pooled stimulated rat and human saliva (equivalent to
1.0 mL residual volume of saliva in humans). Concentrations of efa-
virenz in human saliva were substantially lower than in rat saliva, as
shown in Fig. 5. Changes in saliva pH over efavirenz dissolution time
course are shown in Fig. 6. In both HS and RS saliva pH was shown to
increase over 2min with substantial differences between HS and RS
throughout the dissolution time course.
4. Discussion
Most currently used taste evaluation methods are designed pri-
marily for the assessment of liquid dosage forms [13]. However, these
methods designed for determining taste of liquid dosage forms with
taste-masking agents may not be optimal for solid oral dosage forms
and suspensions. Particulate-based taste-masked formulations aim to
prevent an aversive taste response by reducing the release of the poorly
tasting drug into the oral cavity. Thus, the dissolution properties of the
API in saliva become critical. There is a lack of in vivo preclinical models
that incorporate biorelevant dissolution and thus expose a realistic
concentration to the receptor for particulate-based formulations. To
assess the applicability of rat as an in vivo taste evaluation model for
particulate-based formulations, rat saliva was characterised in this work
for parameters important for drug dissolution and compared to these
parameters in human saliva. Moreover, dissolution of model bitter APIs
were assessed in rat saliva and compared head to head to dissolution in
human saliva. Rat saliva was found to be dramatically different to
human saliva for all tested parameters. The pH of rat saliva was sub-
stantially more alkaline compared to human saliva, as shown in Fig. 2A.
The rat saliva and human saliva pH levels recorded in this study are also
supported by similar findings in literature [28,29,45]. The difference in
pH between rat and human saliva can significantly affect the dissolu-
tion profile of drugs, especially of weakly acidic ionisable APIs and
excipients due to their higher aqueous solubility at higher pH. For ex-
ample, acidic drugs clinically relevant for paediatric use and taste
aversiveness such as efavirenz, diclofenac and chloral hydrate can
achieve higher concentrations in rat oral cavity compared to the human
oral cavity due to this pH effect on solubility. In addition, taste-masking
strategies such as the use of weak base anion exchange resins will not
function in a manner similar to human oral cavity at the higher pH of
rat saliva [10]. The dissimilar pH could also affect other pH dependent
coatings and suspensions. Therefore, this difference in pH between rat
and human saliva could impact the extrapolation of particulate-based
formulation rat taste studies to humans.
The buffer capacity of rat saliva was significantly lower than human
saliva, as displayed in Fig. 2B. As saliva is a buffered aqueous medium
the dissolution rate of sparingly soluble weak acid or weak base drugs
can be affected due to ionic interactions at the microenvironment solid-
liquid interface [46]. The impact the buffer has on drug dissolution is
dependent on several factors, such as ionisation constants of the buffer
and drug, molar concentration of the buffer, buffer capacity, and the
concentration of buffer species reacting with the drug [46]. Therefore,
the results suggest that it is likely that the dissolution of drugs could be
affected by this difference in buffer capacity which could then impact
the correlation between rat and human particulate-based formulation
taste studies.
Previous studies have shown the effect of surface tension on drug
dissolution [47,48]. The surface tension of rat saliva was dramatically
lower than the surface tension of human saliva. The Washburn equation
explains that the penetration of dissolution media is the rate limitingTa
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step to solid dosage form disintegration, and is directly influenced by
media surface tension [49]. Therefore, the disintegration of particulate-
based formulations in the oral cavity will be affected by saliva surface
tension.
From shear rates 1.33–10.0 s−1 rat saliva viscosity was significantly
lower than the viscosity of human saliva. The relationship of viscosity
on drug dissolution rate has shown to be inversely proportional [50].
Using the Noyes-Witney dissolution model, an increase in dissolution
media viscosity would increase the thickness of boundary layers and
decrease the diffusion coefficient [51]. In contrast, the shear rate ex-
perienced in humans from the initial perception of solids within the oral
cavity has shown to be around 50 s−1 [52]. At 50 s−1 no significant
differences in viscosity were observed between rat and human saliva.
However, currently there are no reports of shear rates experienced in
rats for initial perception of solids within the oral cavity, so it is im-
possible to determine how these viscosity differences could affect taste
in vivo. Rheology is known to be a key element in the oral processing of
solid oral dosage forms [52]. Differences in rheology and potential
differences in oral cavity shear could again impact the correlation of
particulate-based taste-masked formulations assessment in a rat model.
The substantial differences observed from the characterisation data
suggest that there could be differences in dissolution of drugs between
human and rat saliva. Therefore, it was important to confirm this as-
sumption by investigating the dissolution of model bitter APIs with
distinct physicochemical properties.
The concentration of sildenafil citrate was found to be significantly
lower in rat saliva compared to human saliva. Conversely, the con-
centration of efavirenz was shown to be significantly higher in rat saliva
compared to human saliva. These differences in dissolution profiles
between the two saliva sources are likely to be due to the differences in
physicochemical properties of saliva. For sildenafil citrate dissolution,
the measurements of dissolution chamber pH for both saliva types was
shown to remain at pH 4.5 after the one-minute time point as shown in
Fig. 4. The immediate reduction in saliva pH likely suggests that the
introduction of sildenafil citrate into saliva had caused dissociation of
the salt back into the sildenafil free base [53]. The pH over the
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Fig. 2. Characterisation of stimulated rat saliva (RS SS) and stimulated human saliva (HS SS). (A) pH of individual stimulated rat saliva samples and pooled
stimulated human saliva (n=24 rat, n=12 human). (B) Buffer capacity of pooled stimulated rat and human saliva (n=12 rat, n=8 human). (C) Surface tension of
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Significant differences were observed for all parameters between rat and human saliva; **** p < 0.0001, * p < 0.05.
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remaining time course in both rat and human saliva was maintained
around pH 4.5, this suggests the differences seen in sildenafil con-
centrations over the time course between the two saliva sources was not
primarily due to pH. Instead, these differences in dissolution for silde-
nafil between the two saliva types may be caused by other saliva
parameters such as mucin content, proteome composition, or ionic
exchange from the salivary pellicle. For efavirenz the difference in
dissolution profile from rat and human saliva was likely due to the
differences in saliva pH. Efavirenz is known to have a pH-dependent
relationship with regards to solubility. Previous studies have shown
that when media pH exceeds pH 8.0, the solubility of efavirenz in-
creases 6-fold compared to the solubility at pH 7.4 [26]. Fig. 6 shows
that the differences in saliva pH are likely to be a main contributing
factor to the differences in EFV concentration. However, in this study
the difference in efavirenz concentration was much greater than 6-fold,
suggesting that other characteristics of rat saliva were also contributors
to the dissolution profile observed.
In order to have a reliable rat taste model to assess particulate-based
taste-masked formulations, and to have direct correlation to human
taste procedures the characteristics of rat saliva should be to some ex-
tent similar to human saliva. The dissolution of drugs would have to be
similar in both rat and human saliva as the media of the oral cavity
would dictate the release of drug from taste-masked formulations.
However, this study has shown that the physicochemical characteristics
of rat saliva are very different from human saliva. Moreover, this was
further confirmed by the dissolution of two model bitter drugs being
completely different in rat versus human saliva. Therefore, the data
suggest that a rat taste model for the assessment of particulate-based
taste-masked formulations would not likely be representative of the
taste response from human taste panels. This is likely to have im-
plications for the adaptation of currently existing BATA models used
successfully for liquid taste masked formulations to particulate for-
mulations. Looking at other common laboratory animals, previous
comparisons have also shown that canine saliva is different to human
saliva as it has higher pH, buffer capacity, and concentration of mi-
nerals [54]. These considerable changes in saliva characteristics be-
tween species suggest that particulate-based taste-masked formulations
should be for now assessed in vivo utilising human taste panels. Further
work is needed to find another suitable species for a preclinical in vivo
model with similar saliva characteristics to humans. Moreover, in vitro
biorelevant oral cavity dissolution models, mimicking physicochemical
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parameters of human saliva and fluid dynamics of oral cavity could
provide a useful alternative to human panels in the future.
5. Conclusion
In this study it has been found that stimulated rat saliva is sig-
nificantly different from stimulated human saliva in terms of pH, buffer
capacity, surface tension, and viscosity. In addition, the dissolution of
two model bitter drugs, sildenafil citrate and efavirenz gave very dif-
ferent concentrations in stimulated rat saliva compared to stimulated
human saliva. These differences suggest that the fate of the particulate-
based dosage forms in the rat oral cavity could be quite different
compared to human oral cavity. This discrepancy in saliva parameters
and dissolution of model drugs suggests that a rat preclinical taste
evaluation method of particulate-based taste-masked formulations
could be not representative of the taste of these particulate-based taste-
masked formulations in humans. Alternative preclinical in vivo models
in other species, or improved biorelevant in vitro models should be
considered instead.
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